Floatz Rating
BB64/100
Confidence
Indicative
Sponsor
Nanjing Leads Biolabs Co.,Ltd
Modality
monoclonal_antibody
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
64High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07281976CT.gov A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07457359CT.gov Neoadjuvant Toripalimab Plus SBRT for Chemo-Resistant Triple-Negative Breast Cancer | — | Recruiting | — | — | — |
NCT07244874CT.gov Sac-TMT Combined With Toripalimab for First-line Treatment of PD-L1 Positive a/mTNBC | — | Not Yet Recruiting | — | — | — |
NCT07256964CT.gov Toripalimab Combined With Anthracycline-free or Anthracycline-containing Chemotherapy as Neoadjuvant Chemotherapy for Early Triple Negative Breast Cancer | — | Not Yet Recruiting | — | — | — |
NCT07040644CT.gov A Study of Sacituzumab Govitecan Plus Toripalimab Versus Toripalimab Plus Nab-Paclitaxel in PD-L1 Positive Advanced TNBC | — | Not Yet Recruiting | — | — | — |
NCT07101614CT.gov A Randomized Study of JS004 and Toripalimab Combined With Chemotherapy vs Toripalimab Combined With Chemotherapy vs Chemotherapy Alone as Neoadjuvant Therapy for Stage II-III Triple-negative Breast Cancer (TNBC). | — | Not Yet Recruiting | — | — | — |
NCT07111832CT.gov A Clinical Trial of SHR-A1811 in the Treatment of Triple-negative Breast Cancer | — | Recruiting | — | — | — |
NCT06991790CT.gov Sacituzumab Govitecan + Toripalimab as First - Line Therapy for Advanced Triple - Negative Breast Cancer and Biomarker Exploration | — | Recruiting | — | — | — |
NCT06735131CT.gov The Optimal Radioimmunotherapy Combinations for Advanced TNBC | — | Recruiting | — | — | — |
NCT06878625CT.gov A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer | — | Recruiting | — | — | — |
Show 11 more trialsShow fewer
NCT06636981CT.gov All Trans Retinoic Acid Combined with Toripalimab+Chemotherapy for Locally Advanced Inoperable or Metastatic Triple Negative Breast Cancer：a Multi-center, Multi-cohort Phase II Trial | — | Recruiting | — | — | — |
NCT06371274CT.gov A Study on the Efficacy and Safety of Oral All-trans Retinoic Acid Combined With Toripalimab in TNBC. | — | Recruiting | — | — | — |
NCT06682195CT.gov Neoadjuvant Chemotherapy Combined With Toripalimab for TNBC (NEOTORCH-BREAST02) | — | Recruiting | — | — | — |
NCT06387628CT.gov LM-108 in Combination With PD-1 Based Treatment for Patients With Recurrent or Metastatic Triple - Negative Breast Cancer | — | Recruiting | — | — | — |
NCT05955105CT.gov A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies | — | Recruiting | — | — | — |
NCT05491694CT.gov To Evaluate the Efficacy of Toripalimab Combined With Chemotherapy After HIFU Induction in the Treatment of Early Triple-negative Breast Cancer | — | Unknown | — | — | — |
NCT06618014CT.gov Neoadjuvant Toripalimab Plus Docetaxel and Carboplatin in Patients With Localized TNBC (NeoTOP) | — | Active Not Recruiting | — | — | — |
NCT04418154CT.gov Neoadjuvant Dose-dense EC Followed by ABX With PD-1 for Triple Negative Breast Cancer Patients | — | Unknown | — | — | — |
NCT03251313CT.gov PD-1(Programmed Death-1) Antibody +GP as First Line Treatment for Triple Negative Breast Cancer(TNBC) Patients | — | Unknown | — | — | — |
NCT04085276CT.gov Toripalimab in Combination With Nab-Paclitaxel For Patients With Metastatic or Recurrent Triple-Negative Breast Cancer (TNBC) With or Without Systemic Treatment | — | Completed | — | — | — |
NCT03777579CT.gov A Study of First-line JS001 and Nab-paclitaxel Versus Palcelbo and Nab-Paclitaxel in Participants With Advanced Recurrent or Metastatic TNBC | — | Suspended | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Triple-Negative Breast Carcinoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Toripalimab (this asset) | Nanjing Leads Biolabs Co.,Ltd | P3 | BB · 64 |
| Carboplatin | M.D. Anderson Cancer Center | P4 | BB |
| Capivasertib | AstraZeneca | P3 | BB |
| Cyclophosphamide | M.D. Anderson Cancer Center | P4 | BB |
| Veliparib | National Cancer Institute (NCI) | P3 | BB |
| Enzalutamide | Nuvation Bio Inc. | P2 | BB |
| Atezolizumab | European Institute of Oncology | P3 | BB |
| Famitinib | Fudan University | P3 | BB |
| Epirubicin | M.D. Anderson Cancer Center | P4 | BB |
+42 more in the Triple-Negative Breast Carcinoma cohort
Other indications for Toripalimab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Renal Cell Carcinoma | — | P3 | BB · 67 |
| Extranodal Nasal NK/T Cell Lymphoma | — | P3 | BB · 66 |
| Small Cell Lung Carcinoma | — | P3 | BB · 64 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Toripalimab in Triple-Negative Breast Carcinoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/toripalimab-triple-negative-breast-carcinoma-36412
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →